Angels for Change Inc

What it reported doing in 2025

We advocate on behalf of any patient facing a life-saving drug shortage, while building strong relationships with patients and stakeholders across the pharmaceutical supply chain to eliminate healthcare crises caused by drug shortages. We operate the nation's only drug shortage hotline, powered by our global supply sharing network. This work has become the nation's center of pharma supply chain trust and is extremely successful in ensuring patient access during market disruptions. Since our founding, our patient advocacy efforts have helped provide access to more than 800,000 life-saving treatments for patients, physicians, and hospitals in need. Continued on schedule o.in 2025, we continued to expand our impact through proactive resilience programs, strategic advocacy initiatives, and national partnerships focused on long-term, systemic solutions that will end drug shortages for all.our work is delivering results: after reaching an all-time high in early 2024, drug shortages declined to a 20-year low in 2025. Demonstrating that proactive solutions and focused, patient centric collaboration during disruption can stabilize supply. Yet there were still hundreds of drugs on shortage and patient care gaps remain. Patients and providers continue to feel the strain of this fragile market, underscoring the need to sustain and scale these efforts. In 2026 and beyond, we will begin to focus on building the supply chain of the future all patients deserve.in 2025, we:- advocated for thousands of patients experiencing life-saving drug shortages-our core mission and highest priority.- maintained a 98% success rate in supporting patient access through our drug shortage hotline (dsh) and global supply sharing network (gssn).- expanded project protect to on shore and safeguard access to critical medications during ongoing and emerging shortages.- continued engagement with the white house, congress, and federal agencies to advance bipartisan, systemic policy solutions.- elevated national awareness through media, speaking engagements, and summitone-the only national conference exclusively dedicated to ending drug shortages.- launched project gold, a proactive national buffer supply model to stabilize supply of vulnerable oncologics, with an initial pilot successfully sustaining access for all us patients to leucovorin during shortage conditions.- strengthened and expanded our coalition of partners across the supply chain to build a more reliable, resilient system centered on patient needs.

Financial Efficiency

• Mission deployment rate: 89.1%; rating input score 89
• Program expense ratio: 84.2%; rating input score 84
• Fundraising efficiency: $14.87 raised per $1 spent on fundraising; rating input score 47; 47th percentile among comparable filings

Transparency & Controls

• Consistency checks: 93.8%; rating input score 94; 25th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: 98.4%; rating input score 98; 50th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 5 of 8 controls in place; rating input score 62
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: Fail
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -5.8%; rating input score 18; 18th percentile among comparable filings
• Total-asset coverage ratio: 0.52; rating input score 25; 25th percentile among comparable filings
• Liabilities to assets ratio: 0.03; rating input score 51; 51st percentile among comparable filings
• Officer compensation ratio: 41.5%; rating input score 3; 3rd percentile among comparable filings

Growth

• Program expense growth: 37.9% per year; rating input score 100; 92nd percentile among comparable filings
• Revenue growth: 30.6% per year; rating input score 100; 91st percentile among comparable filings
• Asset growth: 24.9% per year; rating input score 100; 85th percentile among comparable filings